相关实验视频
Updated: May 23, 2025

08:43
Investigating Intestinal Inflammation in DSS-induced Model of IBD
Published on: February 1, 2012
67.0K
在DSS诱导大肠炎模型中,HS-GC-MS方法用于IBD动态的诊断
Olga Yu Shagaleeva1, Daria A Kashatnikova1,2, Dmitry A Kardonsky1
1Laboratory of Molecular Pathophysiology, Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow, Russia.
Bio-protocol
|May 21, 2025
概括
便中的挥发性有机化合物 (VOC) 可以在早期非侵入性检测炎症性肠病 (IBD). 这项研究使用头部气体染色体质谱法 (HS-GC-MS) 来识别大肠炎模型中的VOC变化,帮助IBD诊断.
科学领域:
- 胃肠病学 胃肠病学
- 代谢学 代谢学 代谢学
- 微生物学 微生物学
背景情况:
- 炎症性肠病 (IBD) 是一个全球性的健康问题,常常无症状的早期阶段.
- 胃肠道微生物群衍生的挥发性有机化合物 (VOC) 的变化与IBD有关.
- 早期发现IBD对于有效的管理和治疗至关重要.
研究的目的:
- 建立一种使用VOCs评估IBD在不同炎症阶段的非侵入性方法.
- 验证用于IBD检测的头部气体染色体质谱法 (HS-GC-MS) 的使用.
- 在DSS诱导的大肠炎模型中,将VOC概况与疾病活性和组织学发现相关联.
主要方法:
- 在Wistar大鼠和C57BL/6小鼠中,硫酸 (DSS) 诱导的大肠炎模型.
- 在便样本上使用头空间气体染色学质谱法 (HS-GC-MS) 进行非侵入性评估.
- 疾病活动指数 (DAI) 和组织病理学检查以确认肠道炎症.
主要成果:
- HS-GC-MS成功检测了DSS诱导大肠炎的急性和缓解阶段的炎症.
- 在便中的VOC相对含量中发现了显著的变化,与炎症相关.
- 该方法在检测肠道炎症方面表现出高灵敏度.
结论:
- HS-GC-MS是一种敏感且非侵入性的工具,用于检测IBD.
- 在便中的VOC分析对早期IBD诊断有希望.
- 这种方法也可用于监测IBD患者的治疗有效性.
关键词:
DSS引起的结肠炎头部空间气色谱质谱学 (HSGCMS)IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD代谢学概况 代谢学概况挥发性有机化合物 (VOC) 是一种挥发性有机化合物.更多相关视频
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
290
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
290
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
103
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
103
Chronic Bowel Disorders: Introduction
375
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
375
Drugs for Treatment of Diarrhea-Predominant IBS
133
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
133

